C2N Diagnostics, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the Alzheimer’s and Parkinson’s Diseases Conference in Vienna, Austria on April 5. Please join us in Vienna and be among the first to learn about exciting new data for the Precivity™ line of blood tests. 12:25 – 12:40 PRECIVITYAD2 TEST ACCURATELY IDENTIFIES BRAIN AMYLOID AND TAU PATHOLOGY IN ADNI PARTICIPANTS ENROLLED IN THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH STUDY. (ID 2534) Room: Hall F2 Presenter: Philip Verghese (United States of America) #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #brainhealth #brainamyloid #ADNI
Senior Vice President, C2N Diagnostics Mass Spectrometry-based biomarkers for neurodegeneration
3dFantastic photo, superb scientist, and great findings !!